A comprehensive promoter landscape identifies a novel promoter for CD133+ in restricted tissues, cancers, and stem cells

Frontiers in Genetics

Volumn 4, Issue OCT, 2013, Pages

  Sompallae, Ramakrishna ^a   Hofmann, Oliver ^a,b   Maher, Christopher A ^c   Gedye, Craig ^d   Behren, Andreas ^d   Vitezic, Morana ^e,f   Daub, Carsten O ^e,g   Devalle, Sylvie ^h   Caballero, Otavia L ⁱ   Carninci, Piero ^e,g   Hayashizaki, Yoshihide ^e,g   Lawlor, Elizabeth R ^j   Cebon, Jonathan ^d   Hide, Winston ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^e RIKEN YOKOHAMA INSTITUTE   (Japan)

^f KAROLINSKA INSTITUTE   (Sweden)

^g RIKEN   (Japan)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

AC133 antigen; Cancer stem cells; Genetic; Human; Melanoma; PROM1 protein; promoter regions; Transcription start site

Indexed keywords

EID: 84892378492     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00209     Document Type: Review

References (63)

1. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. J. Mol. Biol. 215, 403-410. doi: 10.1016/S0022-2836(05)80360-2
2. Amiri, K. I., Ha, H. C., Smulson, M. E., and Richmond, A. (2006). Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-Ribose) polymerase-1. Oncogene 25, 7714-7722. doi: 10.1038/sj.onc.1209751
3. Bailey, T. L., Bodén, M., Buske, F. A., Frith, M., Grant, C. E., Clementi, L., et al. (2009). MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 37, W202-W208. doi: 10.1093/nar/gkp335
4. Bailey, T. L., Bodén, M., Whitington, T., and Machanick, P. (2010). The value of position-specific priors in motif discovery using MEME. BMC Bioinformatics 11:179. doi: 10.1186/1471-2105-11-179
5. Behren, A., Anaka, M., Lo, P.-H., Vella, L. J., Davis, I. D., Catimel, J., et al. (2013). The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res. 26, 597-600. doi: 10.1111/pcmr.12097
6. Bianchi, M. E., and Agresti, A. (2005). HMG proteins: dynamic players in gene regulation and differentiation. Curr. Opin. Genet. Dev. 15, 496-506. doi: 10.1016/j.gde.2005.08.007
7. Bussolati, B., Bruno, S., Grange, C., Buttiglieri, S., Deregibus, M. C., Cantino, D., et al. (2005). Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545-555. doi: 10.1016/S0002-9440(10)62276-6
8. 133+ in glioblastoma. Glia 59, 1974-1986. doi: 10.1002/glia.21239
9. Chiappetta, G., Avantaggiato, V., Visconti, R., Fedele, M., Battista, S., Trapasso, F., et al. (1996). High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13, 2439-2446.
10. Corbeil, D., Fargeas, C. A., and Huttner, W. B. (2001). Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem. Biophys. Res. Commun. 285, 939-944. doi: 10.1006/bbrc.2001.5271
11. Davuluri, R. (2008). The functional consequences of alternative promoter use in mammalian genomes. Trends Genet. 24, 167-177. doi: 10.1016/j.tig.2008.01.008
12. De Hoon, M., and Hayashizaki, Y. (2008). Deep cap analysis gene expression (CAGE): genome-wide identification of promoters, quantification of their expression, and network inference. Biotechniques 44, 627-628, 630, 632. doi: 10.2144/000112802
13. ENCODE Project Consortium. (2004). The ENCODE (ENCyclopedia of DNA Elements) project. Science (New York, NY) 306, 636-640. doi: 10.1126/science.1105136
14. Ernst, J., and Kellis, M. (2010). Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28, 817-825. doi: 10.1038/nbt.1662
15. Ernst, J., Kheradpour, P., Mikkelsen, T. S., Shoresh, N., Ward, L. D., Epstein, C. B., et al. (2011). Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49. doi: 10.1038/nature09906
16. 133+, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells (Dayton, Ohio) 21, 506-508. doi: 10.1634/stemcells.21-4-506
17. 133+, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319, 15-26. doi: 10.1007/s00441-004-1018-z
18. 133++ melanoma cells. Cancer Immunol. Immunother. 58, 1635-1646. doi: 10.1007/s00262-009-0672-0
19. Giannini, G., Kim, C. J., Di Marcotullio, L., Manfioletti, G., Cardinali, B., Cerignoli, F., et al. (2000). Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br. J. Cancer 83, 1503-1509. doi: 10.1054/bjoc.2000.1494
20. 133+/PROM1 expression in glioma stem cells by Sp1/Myc and promoter methylation. Oncogene 32, 3119-3129. doi: 10.1038/onc.2012.331
21. Hamburger, A. W., and Salmon, S. E. (1977). Primary bioassay of human tumor stem cells. Science (New York, NY) 197, 461-463. doi: 10.1126/science.560061
22. Ho Sui, S. J., Fulton, D. L., Arenillas, D. J., Kwon, A. T., and Wasserman, W. W. (2007). oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res. 35, W245-W252. doi: 10.1093/nar/gkm427
23. Hoskins, R. A., Landolin, J. M., Brown, J. B., Sandler, J. E., Takahashi, H., Lassmann, T., et al. (2010). Genome-wide analysis of promoter architecture in Drosophila melanogaster. Genome Res. 21, 182-192. doi: 10.1101/gr.112466.110
24. 2. Int. J. Oncol. 40, 71-79. doi: 10.3892/ijo.2011.1207
25. 133+ expression in chemo-resistant ewing sarcoma cells. BMC Cancer 10:116. doi: 10.1186/1471-2407-10-116
26. Karolchik, D., Kuhn, R. M., Baertsch, R., Barber, G. P., Clawson, H., Diekhans, M., et al. (2008). The UCSC genome browser database: 2008 update. Nucleic Acids Res. 36, D773-D779. doi: 10.1093/nar/gkm966
27. Kawaji, H., Severin, J., Lizio, M., Waterhouse, A., Katayama, S., Irvine, K. M., et al. (2009). The FANTOM web resource: from mammalian transcriptional landscape to its dynamic regulation. Genome Biol. 10, R40. doi: 10.1186/gb-2009-2010-4-r40
28. Kent, W. J. (2002). BLAT-the BLAST-like alignment tool. Genome Res. 12, 656-664. doi: 10.1101/gr.229202
29. Kodzius, R., Kojima, M., Nishiyori, H., Nakamura, M., Fukuda, S., Tagami, M., et al. (2006). CAGE: cap analysis of gene expression. Nat. Methods 3, 211-222. doi: 10.1038/nmeth0306-211
30. Kurosawa, J., Nishiyori, H., and Hayashizaki, Y. (2010). Deep cap analysis of gene expression. Methods Mol. Biol. (Clifton, NJ) 687, 147-163. doi: 10.1007/978-1-60761-944-4_10
31. 133+ a marker of metastatic colon cancer stem cells? J. Clin. Invest. 118, 2021-2024. doi: 10.1172/JCI36046
32. Lee, A., Kessler, J. D., Read, T. A., Kaiser, C., Corbeil, D., Huttner, W. B., et al. (2005). Isolation of neural stem cells from the postnatal cerebellum. Nat. Neurosci. 8, 723-729. doi: 10.1038/nn1473
33. 133+- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 100, 1040-1046. doi: 10.1111/j.1349-7006.2009.01144.x
34. Miraglia, S., Godfrey, W., Yin, A. H., Atkins, K., Warnke, R., Holden, J. T., et al. (1997). A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-5021.
35. 133+: molecule of the moment. J. Pathol. 214, 3-9. doi: 10.1002/path.2283
36. Pal, S., Gupta, R., Kim, H., Wickramasinghe, P., Baubet, V., Showe, L. C., et al. (2011). Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development. Genome Res. 21, 1260-1272. doi: 10.1101/gr.120535.111
37. Pang, B., Fan, H., Zhang, I. Y., Liu, B., Feng, B., Meng, L., et al. (2011). HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis. J. Neurooncol. 106, 543-549. doi: 10.1007/s11060-011-0710-6
38. 133+ is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol. Cancer 10, 94. doi: 10.1186/1476-4598-10-94
39. Pleshkan, V. V., Vinogradova, T. V., and Sverdlov, E. D. (2008). Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. Biochim. Biophys. Acta 1779, 599-605. doi: 10.1016/j.bbagrm.2008.06.002
40. Qin, Z. S., Yu, J., Shen, J., Maher, C. A., Hu, M., Kalyana-Sundaram, S., et al. (2010). HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-seq data. BMC Bioinformatics 11:369. doi: 10.1186/1471-2105-11-369
41. Reeves, R., and Beckerbauer, L. (2001). HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim. Biophys. Acta 1519, 13-29. doi: 10.1016/S0167-4781(01)00215-9
42. Reeves, R., Edberg, D. D., and Li, Y. (2001). Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell Biol. 21, 575-594. doi: 10.1128/MCB.21.2.575-594.2001
43. Rozen, S., and Skaletsky, H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365-386. doi: 10.1385/1-59259-192-2:365
44. Sandelin, A., Alkema, W., Engström, P., Wasserman, W. W., and Lenhard, B. (2004). JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 32, D91-D94. doi: 10.1093/nar/gkh012
45. Shackleton, M. (2010). Normal stem cells and cancer stem cells: similar and different. Sem. Cancer Biol. 20, 85-92. doi: 10.1016/j.semcancer.2010.04.002
46. Shah, S. N., and Resar, L. M. (2012). High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol. Histopathol. 27, 567-579.
47. 133+/Prominin-1. Int. J. Biochem. Cell Biol. 37, 715-719. doi: 10.1016/j.biocel.2004.08.010
48. 133+- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111-2120. doi: 10.1172/JCI34401
49. 133. Blood 103, 2055-2061. doi: 10.1182/blood-2003-06-1881
50. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., et al. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401. doi: 10.1038/nature03128
51. 133+ marks stem cells and early progenitors in mouse small intestine. Gastroenterology 136, 2187-2194 e1. doi: 10.1053/j.gastro.2009.03.002
52. Stewart, J. M., Shaw, P. A., Gedye, C., Bernardini, M. Q., Neel, B. G., and Ailles, L. E. (2011). Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 108, 6468-6473. doi: 10.1073/pnas.1005529108
53. 133+ expression in human gliomas. Cell Res. 18, 1037-1046. doi: 10.1038/cr.2008.270
54. 133+ promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol. Cancer 9, 39. doi: 10.1186/1476-4598-9-39
55. 133+ suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30, 97-105. doi: 10.1038/onc.2010.383
56. 133+(+) Liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through Neurotensin/Interleukin-8/CXCL1 signaling. Hepatology 55, 807-820. doi: 10.1002/hep.24739
57. 133++ cancer stem cells in human solid tumours. PLoS ONE 3:e3469. doi: 10.1371/journal.pone.0003469
58. Tkachenko, A., Ashar, H. R., Meloni, A. M., Sandberg, A. A., and Chada, K. K. (1997). Misexpression of disrupted HMGI architectural factors activates alternative pathways of tumorigenesis. Cancer Res. 57, 2276-2280.
59. von Levetzow, C., Jiang, X., Gwye, Y., von Levetzow, G., Hung, L., Cooper, A., et al. (2011). Modeling initiation of ewing sarcoma in human neural crest cells. PLoS ONE 6:e19305. doi: 10.1371/journal.pone.0019305
60. Wisniewski, J. R., and Schwanbeck, R. (2000). High mobility group I/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation (Review). Int. J. Mol. Med. 6, 409-419.
61. 133+ as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18, 1127-1134. doi: 10.1089/scd.2008.0338
62. 133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012.
63. 133+: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J. Exp. Clin. Cancer Res. 27, 85. doi: 10.1186/1756-9966-27-85